Initial treatment of stage IIIA Hodgkin's disease. Comparison of radiotherapy with combined chemotherapy. British National Lymphoma Investigation.
117 patients with stage IIIA Hodgkin's disease were randomly allocated for treatment in a multicentre trial comparing the results of total nodal irradiation (T.N.I.) with those of combination chemotherapy. Staging procedures for most patients included laparotomy; a few patients whose staging did not include laparotomy were studied separately. Of the 81 patients staged by laparotomy, 40 out of 42 (95%) achieved complete remission (C.R.) after treatment by T.N.I. and 29 out of 39 (74%) achieved C.R. during treatment with mustine hydrochloride, vincristine ("Oncovin"), procarbazine, and prednisone (MOPP) (P=0.018). An analysis of the disease-free survival up to four years favoured the group of patients treated by T.N.I. (P less than 0.01) but differences in overall survival were not statistically significant. In the 36 patients with presumed IIIA disease whose staging did not include laparotomy no significant differences in the incidence of C.R. or rates of disease-free or overall survival were observed. It is concluded that T.N.I. is the optimum initial treatment for patients with IIIA disease whose staging includes laparotomy.
D000293:Adolescent; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007813:Laparotomy; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone